T1	Date 12 16	2019
T2	PROC 44 91	Estudio para evaluar la eficacia y la seguridad
T3	CHEM 95 104	dupilumab
#1	AnnotatorNotes T3	C3660996; dupilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	LIVB 108 125	pacientes adultos
T5	Age 118 125	adultos
T6	DISO 130 150	penfigoide ampolloso
#2	AnnotatorNotes T6	C0030805; Bullous pemphigoid; Disease or Syndrome
T7	PROC 171 280	Estudio multicéntrico, aleatorizado, con doble enmascaramiento, controlado con placebo y con grupos paralelos
T8	PROC 286 320	evaluar la eficacia y la seguridad
T9	CHEM 324 333	dupilumab
#3	AnnotatorNotes T9	C3660996; dupilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	LIVB 337 354	pacientes adultos
T11	Age 347 354	adultos
T12	DISO 359 379	penfigoide ampolloso
#4	AnnotatorNotes T12	C0030805; Bullous pemphigoid; Disease or Syndrome
T13	DISO 404 424	penfigoide ampolloso
#5	AnnotatorNotes T13	C0030805; Bullous pemphigoid; Disease or Syndrome
T14	DISO 432 464	afección cutánea autoinmunitaria
T15	DISO 500 508	ampollas
#6	AnnotatorNotes T15	C0005758; Bulla; Finding
T16	ANAT 519 526	líquido
T17	DISO 551 571	Penfigoide ampolloso
#7	AnnotatorNotes T17	C0030805; Bullous pemphigoid; Disease or Syndrome
T18	DISO 572 575	(PA
T19	LIVB 609 618	pacientes
#8	AnnotatorNotes T19	C0030705; Patients; Patient or Disabled Group
T20	DISO 635 659	manifestaciones clínicas
#9	AnnotatorNotes T20	C0037088; Signs and Symptoms; Sign or Symptom
T21	DISO 663 665	PA
#10	AnnotatorNotes T21	C0001339; Pancreatitis, Acute; Disease or Syndrome | C0162323; Polyarthritis; Disease or Syndrome
T22	DISO 675 682	prurito
#11	AnnotatorNotes T22	C0033774; Pruritus; Sign or Symptom
T23	DISO 684 692	ampollas
#12	AnnotatorNotes T23	C0005758; Bulla; Finding
T24	DISO 695 742	placas eritematosas, eccematosas o urticarianas
T25	PROC 751 771	visitas de selección
T26	LIVB 806 819	participantes
T27	PROC 845 900	confirmación histológica, inmunopatológica y serológica
T28	DISO 905 907	PA
#13	AnnotatorNotes T28	C0001339; Pancreatitis, Acute; Disease or Syndrome | C0162323; Polyarthritis; Disease or Syndrome
T29	PROC 928 934	visita
T30	DISO 989 999	enfermedad
#14	AnnotatorNotes T30	C0012634; Disease; Disease or Syndrome | C0221423; Illness (finding); Sign or Symptom
T31	DISO 1029 1049	penfigoide ampolloso
#15	AnnotatorNotes T31	C0030805; Bullous pemphigoid; Disease or Syndrome
T32	PROC 1104 1124	visitas de selección
T33	PROC 1181 1184	NRS
T34	DISO 1216 1223	prurito
#16	AnnotatorNotes T34	C0033774; Pruritus; Sign or Symptom
T35	LIVB 1241 1264	Personas de ambos sexos
T36	Age 1269 1287	entre 18 y 90 años
T37	PROC 1294 1313	visita de selección
T38	PROC 1346 1379	valoración funcional de Karnofsky
T39	PROC 1386 1405	visita de selección
T40	PROC 1477 1486	protocolo
#17	AnnotatorNotes T40	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T41	DISO 1526 1536	penfigoide
#18	AnnotatorNotes T41	C0030805; Bullous pemphigoid; Disease or Syndrome
T42	Neg_cue 1537 1549	distintos al
T43	DISO 1550 1552	PA
#19	AnnotatorNotes T43	C0001339; Pancreatitis, Acute; Disease or Syndrome | C0162323; Polyarthritis; Disease or Syndrome
T44	Negated 1550 1552	PA
T45	DISO 1573 1575	PA
#20	AnnotatorNotes T45	C0001339; Pancreatitis, Acute; Disease or Syndrome | C0162323; Polyarthritis; Disease or Syndrome
T46	ANAT 1583 1600	membranas mucosas
#21	AnnotatorNotes T46	C0026724; Mucous Membrane; Tissue | C1284117; Entire mucous membrane; Tissue
T47	DISO 1605 1646	penfigoide cicatricial de Brunsting Perry
T48	DISO 1651 1671	penfigoide anti-p200
T49	DISO 1676 1709	epidermólisis ampollosa adquirida
#22	AnnotatorNotes T49	C0079293; Epidermolysis Bullosa Acquisita; Disease or Syndrome
T50	DISO 1715 1717	PA
#23	AnnotatorNotes T50	C0001339; Pancreatitis, Acute; Disease or Syndrome | C0162323; Polyarthritis; Disease or Syndrome
T51	DISO 1722 1736	pénfigo vulgar
#24	AnnotatorNotes T51	C0030809; Pemphigus Vulgaris; Disease or Syndrome | C4303496; Pemphigus of vulva; Disease or Syndrome
T52	LIVB 1755 1764	Pacientes
#25	AnnotatorNotes T52	C0030705; Patients; Patient or Disabled Group
T53	PROC 1786 1798	tratamientos
#26	AnnotatorNotes T53	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T54	DISO 1825 1827	PA
#27	AnnotatorNotes T54	C0001339; Pancreatitis, Acute; Disease or Syndrome | C0162323; Polyarthritis; Disease or Syndrome
T55	CHEM 1837 1893	inhibidores de la enzima convertidora de la angiotensina
#28	AnnotatorNotes T55	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T56	CHEM 1895 1907	penicilamina
#29	AnnotatorNotes T56	C0030817; penicillamine; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T57	CHEM 1909 1919	furosemida
#30	AnnotatorNotes T57	C0016860; furosemide; Organic Chemical · Pharmacologic Substance
T58	CHEM 1921 1931	fenacetina
#31	AnnotatorNotes T58	C0031364; phenacetin; Hazardous or Poisonous Substance · Organic Chemical
T59	CHEM 1934 1972	inhibidor de la dipeptidil peptidasa-4
T60	Neg_cue 1978 1980	no
T61	Dose 1997 2014	una dosis estable
T62	Negated 2001 2014	dosis estable
T63	CHEM 2024 2036	medicamentos
#32	AnnotatorNotes T63	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T64	Duration 2045 2067	un mínimo de 4 semanas
T65	PROC 2080 2099	visita de selección
T66	PROC 2133 2144	tratamiento
#33	AnnotatorNotes T66	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T67	CHEM 2152 2185	antagonista de la IL-4 o la IL-13
T68	CHEM 2192 2201	dupilumab
#34	AnnotatorNotes T68	C3660996; dupilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T69	CHEM 2203 2215	tralokinumab
T70	CHEM 2218 2230	lebrikizumab
T71	PROC 2235 2279	Tratamiento con corticoesteroides sistémicos
T72	Route 2269 2279	sistémicos
T73	Duration 2288 2301	las 2 semanas
T74	PROC 2318 2324	visita
T75	PROC 2337 2378	Tratamiento con corticoesteroides tópicos
T76	Route 2371 2378	tópicos
T77	CHEM 2406 2434	inhibidor de la calcineurina
T78	Route 2435 2441	tópico
T79	CHEM 2444 2455	crisaborole
T80	Route 2456 2462	tópico
T81	Date 2471 2489	la semana anterior
T82	PROC 2495 2501	visita
T83	PROC 2514 2525	Tratamiento
#35	AnnotatorNotes T83	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T84	CHEM 2530 2547	inmunomoduladores
#36	AnnotatorNotes T84	C1527392; Immunomodulators; Immunologic Factor · Pharmacologic Substance
T85	CHEM 2548 2579	inmunodepresores no esteroideos
T86	Neg_cue 2565 2567	no
T87	Negated 2568 2579	esteroideos
T88	CHEM 2589 2610	micofenolato mofetilo
#37	AnnotatorNotes T88	C0209368; mycophenolate mofetil; Organic Chemical · Pharmacologic Substance
T89	CHEM 2612 2623	azatioprina
#38	AnnotatorNotes T89	C0004482; azathioprine; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance
T90	CHEM 2626 2637	metotrexato
#39	AnnotatorNotes T90	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T91	Duration 2647 2660	las 4 semanas
T92	PROC 2677 2683	visita
T93	PROC 2696 2707	Tratamiento
#40	AnnotatorNotes T93	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T94	CHEM 2712 2723	biofármacos
T95	DISO 2737 2739	PA
#41	AnnotatorNotes T95	C0001339; Pancreatitis, Acute; Disease or Syndrome | C0162323; Polyarthritis; Disease or Syndrome
T96	CHEM 2749 2770	fármaco citorreductor
T97	CHEM 2794 2803	rituximab
#42	AnnotatorNotes T97	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T98	Duration 2813 2825	los 12 meses
T99	PROC 2842 2848	visita
T100	PROC 2872 2899	cifra de linfocitos y CD19+
T101	Date 2944 2953	más tarde
T102	CHEM 2963 2974	biofármacos
T103	CHEM 2985 3004	inhibidores de IL-5
T104	CHEM 3005 3017	benralizumab
T105	CHEM 3020 3031	mepolizumab
#43	AnnotatorNotes T105	C0969324; mepolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T106	Duration 3042 3057	las 5 semividas
T107	Duration 3075 3089	las 16 semanas
T108	PROC 3106 3112	visita
T109	CHEM 3151 3166	Inmunoglobulina
#44	AnnotatorNotes T109	C0021027; Immunoglobulins; Amino Acid, Peptide, or Protein · Immunologic Factor
T110	Route 3167 3178	intravenosa
T111	Duration 3187 3201	las 16 semanas
T112	PROC 3218 3224	visita
T113	PROC 3303 3312	protocolo
#45	AnnotatorNotes T113	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
